Simplified phenotyping with dextromethorphan by thin-layer chromatography: Application to clinical laboratory screening for deficiencies in oxidative drug metabolism

Therapeutic Drug Monitoring

Volumn 10, Issue 4, 1988, Pages 490-498

  Guttendorf, Robert J ^a   Wedlund, Peter J ^a   Blake, Jerry ^a   Chang, Shih Ling ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dextromethorphan; Oxidative drug metabolism; Phenotyping; Thin layer chromatography

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LEVORPHANOL;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MALE; OXIDATION REDUCTION REACTION; PHENOTYPE; THIN LAYER CHROMATOGRAPHY; URINE; DRUG METABOLISM; DRUG URINE LEVEL; HEREDITY; HUMAN EXPERIMENT; METHODOLOGY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PHARMACOGENETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; COMPARATIVE STUDY; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; HUMAN; HYDROLYSIS; LEVORPHANOL; MALE; MIDDLE AGE; OXIDATION-REDUCTION; PHENOTYPE; SUPPORT, NON-U.S. GOV'T;

EID: 0023823667     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/00007691-198804000-00021     Document Type: Article

References (37)

1. Price-Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
2. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982;31:23-9.
3. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
4. Wedlund PJ, Aslanian WJ, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
5. Eichelbaum M, Woolhouse NM. Inter-ethnic differences in sparteine oxidation among Ghanians and Germans. Eur J Clin Pharmacol 1985;28:79-83.
6. Brsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57:357-60.
7. Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
8. Dengler HJ, Eichelbaum M. Polymorphismen und Defekte des Arzneimittelstoffwecschels ais Ursache toxischer Reak-tionen. Arzneimittel forsch 1977;27:1836-44.
9. Davies DS, Kann GC, Murray S, Brodie MJ, Boobis AR. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol 1981;11:89-91.
10. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS. Assay and characterization of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 1982; 13:637-45.
11. Boobis AR, Murray S, Kahn GC, Robertz G-M, Davies DS. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 1983;23:474-81.
12. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985;260:9057-67.
13. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications [review]. Clin Pharma-cokinel 1982;7:1-22.
14. Idle JR, Smith RL. The debrisoquine hydroxylation gene: a gene of multiple consequence. In: Lemberger L, Reidenberg MM, eds. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. Bethesda, Maryland: American Society for Pharmacology and Experimental Therapeutics, 1984:148-64.
15. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic considerations [review]. Drugs 1985;29:342-75.
16. Kupfer A, Preisig R. Inherited defects of hepatic drug metabolism [review]. Semin Liver Dis 1983;3:819-25.
17. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of adrenoceptor antagonists: clinical pharmacokinetic considerations. Clin Pharmacokinet 1986;11:1-17.
18. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984;2:517-8.
19. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylator phenotype. Life Sci 1978;22:979-84.
20. Alvan G, von Bahr C, Seideman P, Sjoqvist F. High plasma concentrations of p-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1982;1:333.
21. Dayer P, Kubli A, Kupfer A, Courvoisier F, Balant L, Fabre J. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolizers. Br J Clin Pharmacol 1982;13:750-1.
22. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhex-iline neuropathy. Br Med J 1982;284:295-9.
23. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25:1057-64.
24. Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation. Lancet 1981;1:837-8.
25. Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984;228:605-11.
26. Siddoway LR, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;4:785-91.
27. Idle JR, Oates NS, Shah RR, Smith RL. Protecting poor metabolizers, a group at risk of adverse drug reactions. Lancet 1983;1:1388.
28. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
29. Kupfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986;16:421-33.
30. Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites by reverse-phase high performance liquid chromatography. J Pharm Sci 1984;73:24-9.
31. Bookbinder MJ, Panosian KJ. Correct and incorrect estimation of within-day and between-day variation. Clin Chem 1986;32:1734-7.
32. Hinsvark ON, O'Brien J, Zazulak W, Amsel L, Giering JE. Drug analysis: dextromethorphan, its disposition and determination. Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy. Atlantic City, NJ, 1981;9:333.
33. Pfaff G, Briegel P, Lamprecht I. Inter-individual variation in the metabolism of dextromethorphan. Int J Pharm 1983;14:173-89.
34. Ramachander G, Williams FD, Emele JF. Determination of dextrorphan in plasma and evaluation of bioavailability of dextromethorphan hydrobromide in humans. J Pharm Sci 1977;66:1047-8.
35. Gillilan R, Lanman RC, Mason WD. High pressure liquid chromatographic determination of dextrorphan in human plasma. Anal Lett 1980;13:381-7.
36. East T, Dye D. Determination of dextromethorphan and metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection. J Chro-matogr 1985;338:99-112.
37. Barnhart JW. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 1980;55:43-8.